Glioblastoma Treatment: State-of-the-Art and Future Perspectives

Area of Science:

• Neuro-oncology
• Cancer Therapeutics
• Clinical Research

Background:

• Glioblastoma is the most common and fatal primary brain tumor.
• Current glioblastoma treatment involves surgery, radiotherapy, and temozolomide, with bevacizumab for recurrent cases.
• Despite advances, glioblastoma patients face a poor prognosis, necessitating novel therapeutic strategies.

Purpose of the Study:

• To review current glioblastoma treatment standards.
• To summarize ongoing research and future directions in glioblastoma immunotherapy.
• To explore potential preclinical therapies including synthetic molecules and natural compounds.

Main Methods:

• Literature review of glioblastoma treatment modalities.
• Analysis of current research trends in immunotherapy for glioblastoma.
• Evaluation of preclinical data for novel synthetic and natural compounds.

Main Results:

• Glioblastoma management has seen limited improvement in patient outcomes.
• Immunotherapy, synthetic molecules, and natural compounds show promise in preclinical studies.
• Glioblastoma stem cell inhibition is an emerging area of research.

Conclusions:

• Glioblastoma prognosis remains poor despite extensive research efforts.
• Combined therapeutic strategies integrating immunotherapy, novel compounds, and stem cell inhibition are crucial.
• These combined approaches may enhance standard care and represent the future of glioblastoma management.